EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.946
https://www.valueinhealthjournal.com/article/S1098-3015(23)04076-7/fulltext
Title :
EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04076-7&doi=10.1016/j.jval.2023.09.946
First page :
Section Title :
Open access? :
No
Section Order :
10439